Alpha adrenergic receptor agonists for prevention or treatment of a hematoma, edema, and/or deep vein thrombosis
AssigneeWarsaw Orthopedic, Inc.
InventorVanja Margareta King
Life of this patent
Estimating the term…
Abstract
Effective treatments of hematomas, edema, or other fluid accumulation or deep vein thromboses are provided. Through the administration of an effective amount of at least one alpha adrenergic agonist at or near a target site, one can reduce, prevent or treat edema, or other fluid accumulation or deep vein thromboses.
Claims11
An implantable drug depot useful for reducing, preventing, or treating a hematoma, edema or a deep vein thrombosis in a patient in need of such treatment, the implantable drug depot comprising a therapeutically effective amount of an alpha adrenergic agonist, the drug depot being implantable locally at a site beneath the skin to reduce, prevent or treat a hematoma, edema or a deep vein thrombosis, wherein the drug depot is capable of releasing an effective amount of the alpha adrenergic agonist over a period of at least seven days to about fifteen days and comprises at least one biodegradable polymer comprising poly(D,L-lactide), poly(D,L-lactide-co-caprolactone) or poly(L-lactide-co-caprolactone) or a combination thereof and the polymer has an average molecular weight of from about 5,000 to about 500,000 and a modulus of elasticity in the range of about 1×102 to about 3×105 dynes/cm2, and the drug depot is in the form of a coating disposed on a medical device and the drug depot comprises methoxypoly(ethylene glycol) (mPEG).
An implantable drug depot useful for reducing, preventing, or treating a hematoma, edema or a deep vein thrombosis in a patient, the implantable drug depot comprising a therapeutically effective amount of alpha-2 adrenergic agonist and a polymer;
- wherein the drug depot is implantable locally at a site beneath the skin to reduce, prevent or treat a hematoma, edema or a deep vein thrombosis, and the depot is capable of releasing (i) about 5% to about 20% of the alpha-2 adrenergic agonist relative to a total amount of the alpha-2 adrenergic agonist loaded in the drug depot over a first period of up to 72 hours and (ii) about 21% to about 99% of the alpha-2 adrenergic agonist relative to a total amount of the alpha-2 adrenergic agonist loaded in the drug depot over a subsequent period of up to 6 months and the polymer comprises at least one biodegradable polymer comprising poly(D,L-lactide), poly(D,L-lactide-co-caprolactone) or poly(L-lactide-co-caprolactone) or a combination thereof and the polymer has an average molecular weight of from about 5,000 to about 500,000 and a modulus of elasticity in the range of about 1×102 to about 3×105 dynes/cm2, and the drug depot is in the form of a coating disposed on a medical device and the drug depot comprises mPEG.
Dependencies are inferred from the claim text.